Day: May 15, 2024

CloudMD Announces Go-Private Transaction with CPS Capital

Written by Customer Service on May 15, 2024. Posted in Public Companies.

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (TSXV: DOC, Frankfurt: 6PH) (the “Company” or “CloudMD”), an innovative health services company transforming the delivery of care, and CPS Capital (“CPS Capital”), an entrepreneurial investment firm partnering with businesses and teams to realize their growth goals, are pleased to announce that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which CPS Capital (through an affiliate) (the “Purchaser”) has agreed to acquire all of the outstanding common shares (the “Shares”) of CloudMD for cash consideration of C$0.04 per Share (the “Transaction”). The Transaction is the culmination of a strategic and liquidity review that the Special Committee (as defined below) has been engaged in since July 2023, with the assistance...

Safe and Green Development Corporation Reports First Quarter 2024 Financial Results and Provides a Business Update

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

MIAMI, May 15, 2024 (GLOBE NEWSWIRE) — Safe and Green Development Corporation (NASDAQ: SGD) (“SG Devco” or the “Company”) today reported financial results for the three months ended March 31, 2024 and provides a business update. Operational highlights from the first quarter of 2024:Initiated a Strategic Property Monetization Executed Contract to Sell St Mary’s Site for $1.35M Acquired XENE Real Estate AI Software Secured Financing for Norman Berry Expansion in Atlanta, GeorgiaDavid Villarreal, CEO of Safe and Green Development Corporation, remarked, “The first quarter has proven to be an exhilarating period marked by numerous achievements that we believe has positioned us as an integral player in the real estate industry across multiple domains. Our upcoming sale of the St. Mary property, which will result in substantial...

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

Key Highlights:Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease planned to begin H1-2024. GLP toxicology studies for Inflammasome ASC Inhibitor IC 100 scheduled to begin H1-2024, with planned Investigational New Drug (IND) submission Q4-2024, and Phase 1 clinical trial initiation Q1-2025.Atherosclerosis preclinical data readout for Inflammasome ASC Inhibitor IC 100 on schedule for H1-2024. Initiation of preclinical study to assess Inflammasome ASC Inhibitor IC 100 for obesity-associated metabolic comorbidities scheduled to begin Q2-2024 with completion expected by year’s end. Raised $2.7 million from exercising of investor warrants.WESTON, Fla., May 15, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq:...

Kartoon Studios Continues Execution of Growth Strategy With Profitability Targeted for Q2 2025; Provides Business Update for the First Quarter of 2024

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

Kartoon Channel!’s Streaming Business Achieved Profitability in the First Quarter of 2024 and Continues Growth; User Rankings in Apple App Store Now Beat Disney+; Operational Efficiencies Expected to Drive Company-Wide Profitability Direct Operating Costs Reduced by Over 60% in the First Quarter of 2024 Compared to Same Period in 2023; 29% Reduction Sequentially Compared to the Fourth Quarter of 2023 Flagship Brand, “Stan Lee Universe,” Grows Across Multiple Sectors: New Store on Amazon; New Partnership with World’s Largest Digital Collectibles Platform, “VeVe” for Collectibles; and New YouTube Channel, ‘Stan Lee Presents,’ Debuts with Over 300,000 Subscribers, Driving Revenues and Enhancing Global Fan Engagement, with Marvel Mastermind Company Launches New AI Initiative Using Nvidia Omniverse, Revolutionizing Animation...

Lifeward Reports First Quarter 2024 Financial Results

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

Q1’24 revenue of $5.3M is up 340% vs. Q1’23 and at the midpoint of Lifeward’s guidance range Newly established Medicare payment for ReWalk Personal Exoskeleton favorably impacts Q1’24 results Medicare Administrative Contractors (“MACs”) approve 14 claims since fee schedule established MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2024 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced its financial results for the three months ended March 31, 2024. Recent Highlights and Milestones for LifewardThe Centers for Medicare & Medicaid Services...

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3 NAVIGATE study of belapectin in liver cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) NAVIGATE trial remains on track for interim top-line readout late in the fourth quarter of 2024NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “This quarter we remained laser-focused on progressing the NAVIGATE Phase 2b/3 trial of belapectin, which has a Fast Track Designation from the U.S. Food & Drug...

Airship AI Reports First Quarter 2024 Financial Results

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

Strong First Quarter 2024 Net Revenues of $10.6 Million Support Fiscal Year 2024 Triple-Digit Revenue Growth & Positive Cash Flow Objectives First Quarter 2024 Net Revenues of $10.6 Million Represent 84.5% of the Company’s Full Year Revenue in 2023 Awarded Second Contract by DOJ Agency for $2.35 Million for Company’s Outpost AI Appliance to Support Emerging Public Safety and Investigative Requirements REDMOND, Wa., May 15, 2024 (GLOBE NEWSWIRE) — Airship AI Holdings, Inc. (NASDAQ: AISP) (“Airship AI” or the “Company”), a leader in AI-driven video, sensor, and data management surveillance solutions, today reported its financial and operational results for the first quarter ended March 31, 2024. Q1 2024 Financial HighlightsNet revenues for the quarter ended March 31, 2024 were $10.6 million. Gross profits for the quarter ended...

PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer Expanded Global Intellectual Property Surrounding Versamune® Platform PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today provided a business update and reported financial results for the first quarter of 2024. The press release will be available in the Investor Relations section of the Company’s website at www.pdsbiotech.com. Recent DevelopmentsHosted a Key Opinion Leader event on May 8, 2024, during which prominent experts...

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

– CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024- – Completed up to $149.4 million private placement with leading healthcare investors in early 2Q 2024 – BOSTON, May 15, 2024 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the first quarter ended March 31, 2024. “Building on a year of high operational and clinical achievement, already in 2024, we have strengthened our financial resources and published data that further positions our lead clinical program, neflamapimod, as a highly differentiated, potential first-to-market treatment...

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Written by Customer Service on May 15, 2024. Posted in Earnings Releases And Operating Results.

Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking place in Milan, Italy from June 5-8, 2024 End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) expected in the second quarter of 2024 Preparations are underway to start a pivotal Phase 3 trial evaluating denifanstat in patients with metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2024 Anticipated cash runway through 2025 with cash, cash equivalents and marketable securities totaling $193.7 million as of March 31, 2024 SAN MATEO, Calif., May 15, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional...

Day: May 15, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals